Drug guidance
Dolutegravir with lamivudine for treating Human Immunodeficiency Virus type 1 (HIV-1) infection
Condition
Infections
19 December 2022
Published on 19 Dec 2022
Last Updated on 19 Dec 2022
Guidance Recommendations
The Ministry of Health's Drug Advisory Committee has recommended:
Dolutegravir 50 mg/lamivudine 300 mg tablet for treating Human Immunodeficiency Virus type 1 (HIV-1) infection
in view of acceptable proposal from the company.
Funding status
Dolutegravir 50 mg/lamivudine 300 mg tablet is recommended for inclusion on the MOH Standard Drug List (SDL) from 1 February 2023.
Information on antiretroviral therapies previously recommended by the Drug Advisory Committee can be found in the Technology Guidance published on 1 September 2020 (Antiretroviral therapies for treating Human Immunodeficiency Virus type 1 (HIV-1) infection).